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we evaluate potential precipitating factors for hospitalization for heart failure and shock. Methods Using
Swiss claims data (2014–2015), we evaluated the association between hospitalization for heart failure and
shock, and prescription of oral potassium supplements, non-steroidal anti-inflammatory drugs (NSAIDs),
and amoxicillin/clavulanic acid. We conducted case-crossover analyses, where exposure was compared
for the hazard period and the primary control period (e.g., 1–30 days before hospitalization vs. 31–60
days, respectively). Conditional logistic regression was applied and subsequently adjusted for addressing
potential confounding by disease progression. Sensitivity analyses were conducted and stratification for
co-medication was performed. Results We identified 2185 patients hospitalized with heart failure or
shock. Prescription of potassium supplements, NSAIDs, and amoxicillin/clavulanic acid was significantly
associated with an increased risk for hospitalization for heart failure and shock with crude odds ratios
(OR) of 2.04 for potassium (95% CI 1.24–3.36, p = 0.005, 30 days), OR 1.8 for NSAIDs (95% CI 1.39–
2.33, p < 0.0001, 30 days), and OR 3.25 for amoxicillin/clavulanic acid (95% CI 2.06–5.14, p < 0.0001, 15
days), respectively. Adjustment attenuated odds ratios, while the significant positive association remained
(potassium OR 1.70 (95% CI 1.01–2.86, p = 0.046), NSAIDs OR 1.50 (95% CI 1.14–1.97, p = 0.003),
and amoxicillin/clavulanic acid OR 2.26 (95% CI 1.41–3.62, p = 0.001).
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Abstract
Purpose Heart failure is among the leading causes for hospitalization in Europe. In this study, we evaluate potential precipitating
factors for hospitalization for heart failure and shock.
Methods Using Swiss claims data (2014–2015), we evaluated the association between hospitalization for heart failure and shock,
and prescription of oral potassium supplements, non-steroidal anti-inflammatory drugs (NSAIDs), and amoxicillin/clavulanic
acid. We conducted case-crossover analyses, where exposure was compared for the hazard period and the primary control period
(e.g., 1–30 days before hospitalization vs. 31–60 days, respectively). Conditional logistic regression was applied and subse-
quently adjusted for addressing potential confounding by disease progression. Sensitivity analyses were conducted and stratifi-
cation for co-medication was performed.
Results We identified 2185 patients hospitalized with heart failure or shock. Prescription of potassium supplements, NSAIDs, and
amoxicillin/clavulanic acid was significantly associated with an increased risk for hospitalization for heart failure and shock with crude
odds ratios (OR) of 2.04 for potassium (95% CI 1.24–3.36, p = 0.005, 30 days), OR 1.8 for NSAIDs (95% CI 1.39–2.33, p < 0.0001,
30 days), and OR 3.25 for amoxicillin/clavulanic acid (95% CI 2.06–5.14, p< 0.0001, 15 days), respectively. Adjustment attenuated
odds ratios, while the significant positive association remained (potassium OR 1.70 (95% CI 1.01–2.86, p= 0.046), NSAIDs OR 1.50
(95% CI 1.14–1.97, p = 0.003), and amoxicillin/clavulanic acid OR 2.26 (95% CI 1.41–3.62, p= 0.001).
Conclusion Prescription of potassium supplements, NSAIDs, and amoxicillin/clavulanic acid is associated with increased risk for
hospitalization. Underlying conditions such as pain, electrolyte imbalances, and infections are likely contributing risk factors.
Physicians may use this knowledge to better identify patients at risk and adapt patient management.
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Introduction
Heart failure (HF) is among the leading causes for hospital-
ization in Europe, especially in the elderly [1], with an
estimated prevalence of 1–2% in the western world [2].
Gaining insight into the development of patients’
healthcare-seeking behavior towards hospitalization and sub-
sequent identification of risk factors for HF decompensation
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is of great importance for improved risk stratification and
management [3].
The American Heart Association released a list of
medications that could exacerbate HF [4], covering
drugs from thirteen distinct therapeutic classes.
Unfortunately, prescriptions for these medications in
HF patients are still common. A study evaluating
National Health and Nutrition Examination Survey data
from the USA found a prevalence of 48% of heart fail-
ure exacerbating medication use [5].
Examples for common drug mechanisms that may
favor HF deterioration comprise direct myocardial tox-
icity and negative inotropic or chronotropic effects, but
drugs may also exacerbate hypertension, deliver high
sodium loads, or cause drug-drug interactions that may
limit the beneficial effects of (other) HF medications
[4]. Several studies have assessed the association be-
tween prescriptions of non-steroidal anti-inflammatory
drugs (NSAIDs) and HF hospitalization [6–11]. The hy-
pothesized underlying mechanism is the inhibition of
the prostaglandin synthesis, potentially resulting in re-
duced renal perfusion, glomerular filtration rate, and in-
creased peripheral systemic resistance [7].
While medications themselves may be risk factors for
decompensation or development of HF, they can also
serve as proxies for acute conditions presenting poten-
tial risk factors. Conditions such as arrhythmia, worsen-
ing renal function, and infections [12, 13] are common
complications in patients suffering from HF and were
described to be precipitating factors for HF hospitaliza-
tion [3, 14–18]. Additionally, electrolyte imbalances ap-
pear frequently in HF patients [19–22], especially as
several drugs commonly used in heart failure treatment
may lead to hypo- or hyperkalemia, respectively [23,
24]. Although prescription of potassium supplements
was previously described to be associated with HF hos-
pitalization in the long-term [22], and “infection” is re-
ported to be a common precipitating factor, neither pre-
scriptions of potassium nor amoxicillin/clavulanic acid
have been assessed as acute risk factors for heart failure
hospitalization.
Objective
The objective of this study was to evaluate the prescrip-
t ion of potass ium supplements , NSAIDs, and
amoxicillin/clavulanic acid as precipitating factors for
hospitalization for heart failure and shock. The develop-
ment of patients’ healthcare-seeking behavior over time
towards hospitalization was assessed and used to ad-
dress potential confounding for disease progression.
Methods
Claims data
We conducted three case-crossover analyses using
anonymized health insurance data on Swiss adults. The
dataset was provided by the Helsana Group, which is one of
the largest health insurance companies in Switzerland cover-
ing approximately 1.2 million individuals (compulsory health
insurance) [25]. While health insurance is mandatory for all
residents of Switzerland, residents are free to choose their
preferred insurance provider. The recorded insurance claims
cover all healthcare invoices submitted to the Helsana Group
for reimbursement [25]. We obtained data from the years
2014–2015.
Our dataset included patient demographics and records of
utilized healthcare including claimed drug prescriptions, hos-
pitalizations, and physician visits. Patients were required to
have at least five drug prescriptions within a calendar year
and no private additional health insurance. Hospitalization
was identified using Swiss Diagnosis Related Groups
(SwissDRGs) [26], which is used for the invoicing of inpatient
hospitalization services. Based on specific criteria such as the
primary and secondary diagnoses, treatments, and degree of
severity [27], each hospitalization is assigned to a SwissDRG.
Due to the legal requirements in Switzerland, no explicit di-
agnoses were accessible in health insurance data. Outpatient
physician visits and diagnostic procedures performed in the
outpatient setting were identified using TARMED codes [28].
Study design
Three independent case-crossover studies were conducted to
study oral potassium supplements, NSAIDs, and amoxicillin/
clavulanic acid as potential risk factors for hospitalization.
The case-crossover design is ideal to assess associations be-
tween transient risk factors, such as short-term medication
utilization, and outcomes with abrupt onset [29], such as hos-
pitalization for heart failure or shock. The design controls for
time-invariant covariates [29, 30], thereby minimizing the po-
tential for confounding due to stable (measurable and immea-
surable) risk factors [9]. As a case-only design, patients serve
both as cases and their own controls. Since exposure to potas-
sium supplements, NSAIDs, and antibiotics is considered to
be a transient effect, each patient can be “exposed” and “not
exposed” at different time periods. For each patient, exposure
in the “hazard” period immediately preceding the outcome
was compared with exposure in “control” period(s) earlier in
time [29, 31]. The main study design is displayed in Fig. 1 a.
Sensitivity analyses included introducing a single washout
period to prevent exposure overlapping from the control into
the subsequent hazard period, using multiple control periods
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simultaneously, thereby minimizing the effect of confounding
by disease progression or exposure misclassification, and
shortening of the time periods (Fig. 1b–d). Additionally, we
excluded patients with all-cause hospitalizations within the
180-day observation period, as previous studies found recent
hospitalizations to be an independent risk factor for hospital-
ization for heart failure [6].
Case selection
All patients with hospitalizations for heart failure and shock
were identified as cases using SwissDRG codes (F62A, F62B,
and F62C, Supplement Table S1) [26]. For each case, the first
hospitalization within the study period was defined as index
hospitalization. An observation period of at least 180 days
prior to the index hospitalization was required, and patients
were excluded if they had a nursing home stay during that
period. The inclusion process is displayed in Fig. S1 in the
supplement in detail.
Exposure definition
Drug prescriptions were identified using 5th-level Anatomical
Therapeutic Chemical (ATC) code [32]. The primary expo-
sures of interest were oral potassium supplements (ATC:
A12BA), NSAIDs (ATC: M01AA, M01AB, M01AC,
M01AE, M01AG, M01AH, M01AX12), and amoxicillin/
clavulanic acid (ATC: J01CR02). Once the respective drug
was prescribed at any time within the hazard or control period,
the patient was considered to be “exposed” for that period.
Statistical analysis
Data were analyzed using R software (version 3.4.0). For each
patient, demographic parameters, claimed drug prescriptions,
and utilized healthcare such as hospitalizations, physician
visits, and diagnostics/laboratory procedures were analyzed
within the 180-day observation period prior to index hospital-
ization. For dichotomous variables, absolute and relative
Fig. 1 Case-crossover design. As a case-only design, patients serve both
as cases and their own controls. Main analysis: For each patient, exposure
in the “hazard” period immediately preceding the outcome was compared
with exposure in the “direct control” period earlier in time (a). Hazard and
control period were equal in length. Sensitivity analyses: Introduction of a
single washout period to prevent exposure overlapping from the control
into the subsequent hazard period (b). Inclusion of multiple control pe-
riods simultaneously to assess the impact of more distant periods and to
account for persistent drug use (c). Finally, we evaluated shorter time
periods for hazard and control periods (d)
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frequencies were calculated. For continuous variables, me-
dians and interquartile range (IQR) were provided. For trend
analysis, we visualized the frequency of daily outpatient phy-
sician visits towards index hospitalization. To reduce short-
term variations, visits were binned into 7-day intervals.
Based on the binned visits, a Spearman correlation coefficient
was calculated.
For the case-crossover study, we identified discordant pairs
and calculated Mantel-Haenszel odds ratio estimates (OR,
with 95% confidence intervals) using conditional logistic re-
gression to compare the odds of exposure to one of the drugs
of interest in the hazard period to the exposure in the control
periods. Adjusted ORs were calculated to control for the po-
tential of time-variant confounding resulting from disease pro-
gression and deterioration of the ejection fraction. We concur-
rently adjusted for the number of outpatient physician visits
per time period and the co-prescription of high-ceiling di-
uretics (sulfonamides, C03CA).
The hazard and control periods were defined according to
the exposure of interest as follows: Potassium: 30 days (to
cover acute hypokalemia and account for possible potassium
accumulation); NSAIDs: 30 days (in accordance with previ-
ous studies [6, 8, 9, 11, 33]); and amoxicillin/clavulanic acid:
15 days (to allow for treatment durations of usually 1–2 weeks
depending on indication and severity). Shortened time periods
were used as sensitivity analyses (Fig. 1d): Potassium and
NSAIDs (20- or 14-day periods) and amoxicillin/clavulanic
acid (10- or 7-day periods).
Additional analyses
The acute conditions of “pain” and “bacterial infection”
serve as the indication for NSAIDs and amoxicillin/
clavulanic acid. As these conditions may present risk
factors on their own, we subsequently conducted addi-
tional case-crossover studies: To evaluate the overall
indication of “pain,” we independently evaluated para-
cetamol, metamizole sodium, and opioids as drugs de-
fining “exposure” instead of NSAIDs. Accordingly, we
evaluated “bacterial infection” as a risk factor and con-
ducted a case-crossover study for patients with other
antibiotic classes.
Finally, we stratified the analyses to examine the role
of interacting co-medications. For potassium supple-
ments, we evaluated potassium-sparing and potassium-
depleting co-medication (ace-inhibitors/sartans, high-
ceiling diuretics (sulfonamides)) [34]; for NSAIDs, co-
medication with diuretics, ace-inhibitors/sartans, antico-
agulants, and platelet inhibitors was evaluated. For
amoxicillin/clavulanic acid, we repeated the primary
analysis in patients suffering from asthma or chronic
obstructive pulmonary disease (COPD).
Results
Patient characteristics and healthcare utilization
A total of 2185 patients met our inclusion criteria. A summary
of the patients’ characteristics is provided in Table 1. Patients
were old and had a median age over 80 years. Approximately
one-third of the patients were previously hospitalized for other
causes, highlighting disease burden. A substantial amount of
them experienced other cardiac-related hospitalizations.
Outpatient physician visits
Most patients (95.3%) had at least one physician office visit
within 180 days prior to index hospitalization. Most visits were
performed by general practitioners or specialists for internal
medicine (63.6%), followed by ophthalmologists, outpatient
hospital departments, and cardiologists. With respect to the fre-
quency of outpatient visits, a significant trend for increase to-
wards index hospitalization was found (Spearman ρ = 0.56, p =
0.0499, Supplement Fig. S2). A total of 677 patients (31%) had
an outpatient visit at the day of index hospitalization.
Drug prescriptions
Most frequent co-medication were high-ceiling diuretics (sul-
fonamides), with 31.2% and 62.4% of patients receiving at
least one filled prescription within 30 days and 180 days, re-
spectively. Beta-blocking agents, proton-pump inhibitors,
platelet inhibitors, and paracetamol were among the 5 most
frequently prescribed drug classes both within 30 days and
180 days (Supplement Table S2). Within 30 days prior to
index hospitalization, 1403 patients (64.2%) received a pre-
scription of a new drug class. At least one new cardiac therapy
was prescribed in 555 patients (39.6%) (ATC starting with
“C”). Most frequent new drug classes prescribed were high-
ceiling diuretics (sulfonamides) (n = 184), beta-blocking
agents (n = 130), paracetamol (n = 129), proton pump inhibi-
tors (n = 112), and pyrazolones (n = 96) (Supplement
Table S3). Eighty-eight patients received a new prescription
for amoxicillin/clavulanic acid. As previously mentioned, a
high number of patients received NSAIDs (n = 104) and sev-
eral patients were prescribed potassium supplements (n = 33).
Case-crossover study
Prescription of potassium supplements and non-steroidal anti-
inflammatory drugs was significantly associated with an in-
creased probability for hospitalization for heart failure and
shock with odds ratios of 2.04 for potassium (95% CI 1.24–
3.36, p = 0.005, 30 days) and 1.8 for NSAIDs (95% CI 1.39–
2.33, p < 0.0001, 30 days) in all 2185 patients. The strongest
association was found for amoxicillin/clavulanic acid, with an
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odds ratio of 3.25 (95% CI 2.06–5.14, p < 0.0001, 15 days)
(Table 2). Sensitivity analyses introducing a single washout
period and the use of multiple control windows confirmed this
positive association. Odds ratios for shorter time periods are
displayed in Table S4 in the supplement.
To evaluate potential confounding by previous hospitaliza-
tions, we repeated the primary analysis in a subset of 1444 pa-
tients without prior hospitalization. Odds ratios of 2.64 for potas-
sium (95%CI 1.32–5.28, p = 0.0062), 2.07 for NSAIDs (95%CI
1.51–2.85, p < 0.0001), and 3.37 for amoxicillin/clavulanic acid
(95%CI 1.93–5.90, p < 0.0001) were slightly but not significant-
ly elevated compared with the total patient population.
Adjustment for visits and prescription of high-ceiling diuretics
attenuated the odds ratios for all three drug classes, while the
significant positive association remained (Table 2). Subgroup
analyses were performed for potentially interacting co-medica-
tion. Results are displayed in Table S5 in the supplement.
Treatment with metamizole sodium, paracetamol, and opi-
oids was each significantly associated with hospitalization for
heart failure and shock. Our analysis showed a significant
Table 1 Demographics and healthcare utilization
All patients Potassium supplement NSAIDs Amoxicillin/clavulanic acid
N 2185 118 543 318
DRG “Heart failure and shock” (N, %)
With severe co-morbidities (F62A, F62B) 572 (26.2%) 37 (31.4%) 130 (23.9%) 103 (32.4%)
Without severe co-morbidities (F62C) 1613 (73.8%) 81 (68.6%) 413 (76.1%) 215 (67.6%)
Age (Median, IQR) 82.6 (75.9, 87.9) 81.3 (74.2, 86.5) 82.0 (75.9, 87.2) 81.5 (73.6, 87.2)
Gender (F) (N, %) 1092 (50.0%) 65 (55.1%) 296 (54.5%) 124 (39.0%)
Previous hospitalizations (N, %)
All other causes
30 days 267 (12.2%) 19 (16.1%) 82 (15.1%) 44 (13.8%)
180 days 741 (33.9%) 58 (49.2%) 196 (36.1%) 149 (46.9%)
Cardiac-relateda
30 days 56 (2.6%) 9 (7.6%) 16 (2.9%) 6 (1.9%)
180 days 259 (11.9%) 23 (19.5%) 58 (10.7%) 46 (14.5%)
Number of visits (Median, IQR)
30 days 2 (1, 3) 3 (1, 4) 2 (1, 3) 2 (1, 4)
180 days 8 (4, 12) 10 (7, 17) 9 (5, 13) 10 (7, 14)
Number of drugs (Median, IQR)
180 days 13 (9, 17) 16 (13, 23) 15 (11, 20) 16 (11, 14)
Laboratory assessmentb (N, %)
BNP 30 days 245 (11.2%) 19 (16.1%) 73 (13.4%) 34 (10.7%)
180 days 489 (22.4%) 39 (33.1%) 125 (23.0%) 74 (23.3%)
GFR 30 days 767 (35.1%) 71 (60.2%) 210 (38.7%) 149 (46.9%)
180 days 1539 (70.4%) 104 (88.1%) 413 (76.1%) 255 (80.2%)
Potassium 30 days 628 (28.7%) 72 (61.0%) 161 (29.7%) 118 (37.1%)
180 days 1315 (60.2%) 107 (90.7%) 339 (62.4%) 219 (68.9%)
Diagnostic proceduresc (N, %)
Electrocardiography 30 days 396 (18.1%) 28 (23.7%) 121 (22.3%) 75 (23.6%)
180 days 855 (39.1%) 53 (44.9%) 234 (43.1%) 147 (46.2%)
Echocardiography 30 days 136 (6.2%) 11 (9.3%) 37 (6.8%) 18 (5.7%)
180 days 390 (17.8%) 28 (23.7%) 100 (18.4%) 62 (19.5%)
F62A: Heart failure or shock with severe comorbidities and dialysis, reanimation, or additionally complicating diagnosis; F62B: Heart failure or shock
with severe comorbidities but without dialysis, reanimation, or additionally complicating diagnosis; F62C: Heart failure or shock without severe
comorbidities; IQR, interquartile range; BNP, brain natriuretic peptide; GFR, glomerular filtration rate
a Previous cardiac-related hospitalizations were derived from the major diagnostic categories (SwissDRG)
bNumber of patients with at least one measure of the respective test within 30 days or 180 days prior to hospital admission. No laboratory values were available
cOnly tests performed in the outpatient setting were assessed
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positive association with macrolides, but no relevant associa-
tion with fluoroquinolones (Table 3).
Discussion
Our results confirmed previous studies that identified an in-
creased risk for prescription of NSAIDs and heart failure hos-
pitalization. Additionally, prescription of oral potassium sup-
plements and amoxicillin/clavulanic acid was significantly as-
sociated with higher risk for hospitalization.
In a recent review, Greene et al. [35] proposed to intensify
the interventions in the outpatient setting if heart failure dete-
riorates to prevent hospitalization. We found increasing phy-
sician contact prior to hospitalization. Increasing frequencies
of visits may indicate disease progression and can frame the
time period for intensification of patient management.
Therefore, evaluating precipitating factors is important. In ac-
cordance with the literature, most visits were issued by general
practitioners, suggesting that they were primarily treating the
HF patients [2].
Potassium
Potassium supplements are frequently used to balance hypo-
kalemia, which is a common complication in HF patients who
are on diuretic treatment [19, 22] and on its own can be a
proxy for increased diuretic use. Electrolyte imbalances may
be a risk factor for exacerbation of cardiac disorders and po-
tassium supplements can both be interpreted as proxy for hy-
pokalemia and risk factor for hyperkalemia in case of over-
use. Our main analysis showed a significant association with
heart failure hospitalization. Within 1–30 days prior to index
hospitalization, some discordant patients in the hazard period
had prescriptions for antibiotics, while no discordant patient in
the control period was prescribed antibiotics. We therefore
repeated the main analysis in patients without any prescription
Table 3 Comparison to other classes of pain medication and antibiotics
Windows (days) Effect N Discordant pairs
Hazard period Control period ORMH (95% CI) With drug (all patients) Hazard; control
Comparison to other classes of pain medication
NSAIDs 1–30 31–60 1.80 (1.39–2.33)*** 543 (2185) 160; 89
Metamizole sodium
Patients w/o NSAIDs 1–30 31–60 1.95 (1.35–2.82)*** 237 (1642) 84; 43
Patients w/ and w/o NSAIDs 1–30 31–60 2.09 (1.56–2.80)*** 370 (2185) 140; 67
Paracetamol
Patients w/o NSAIDs 1–30 31–60 1.45 (1.15–1.82)** 606 (1642) 175; 121
Patients w/ and w/o NSAIDs 1–30 31–60 1.57 (1.29–1.90)*** 884 (2185) 268; 171
Opioids
Patients w/o NSAIDs 1–30 31–60 1.46 (1.00–2.12)* 228 (1642) 67; 46
Patients w/ and w/o NSAIDs 1–30 31–60 1.87 (1.36–2.55)*** 372 (2185) 112; 60
Comparison to other classes of antibiotics
Amoxicillin/clavulanic acid
Patients w/o other antibiotics 1–15 16–30 3.60 (2.03–6.38)*** 219 (1675) 54; 15
Patients w/ and w/o other antibiotics 1–15 16–30 3.25 (2.06–5.14)*** 318 (2185) 78; 24
Macrolidesa
Patients w/o amoxicillin/clavulanic acid 1–15 16–30 2.50 (1.10–5.68)* 78 (1867) 20; 8
Patients w/ and w/o amoxicillin/clavulanic acid 1–15 16–30 2.73 (1.37–5.44)** 107 (2185) 30; 11
Fluoroquinolonesb
Patients w/o amoxicillin/clavulanic acid 1–15 16–30 0.93 (0.55–1.57) 188 (1867) 27; 29
Patients w/ and w/o amoxicillin/clavulanic acid 1–15 16–30 1.12 (0.70–1.78) 239 (2185) 38; 34
ORMH, Mantel-Haenszel odds ratio; 95% CI, 95% confidence interval for ORMH; Discordant pairs, patients exposed in hazard period but not in control
period or patients exposed in control period but not in hazard period. *p < 0.05, **p < 0.01, ***p < 0.001
aNumber of patients with macrolide prescriptions: n = 107; number of macrolide prescriptions: n = 141; stratified for macrolide: erythromycin: n = 4,
clarithromycin: n = 89; azithromycin: n = 48
bNumber of patients with fluoroquinolone prescriptions: n = 239; number of fluoroquinolone prescriptions: n = 324; stratified for fluoroquinolones:
ofloxacin: n = 1; ciprofloxacin: n = 216; norfloxacin: n = 39; levofloxacin: n = 28; moxifloxacin: n = 40
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of an antibiotic during the observation period (n = 1456). An
odds ratio of 1.8 was found (95% CI 0.96–3.38, p = 0.068).
Interestingly, significantly more discordant patients with
potassium supplements in the hazard period had closer lab
assessments (potassium and renal function) compared with
discordant patients in the control period. Closer monitoring
itself may indicate a deteriorated general condition.
Therefore, risk attributed to potassium supplements may be
overestimated.
With respect to the literature, hyperkalemia was reported to
increase risk for mortality and readmission in patients hospital-
ized for HF [21] andwas strongly associated with reduced renal
function [23, 24]. Additionally, an increased risk for HF hospi-
talization was reported after an event of hyperkalemia [23].
Co-medication influencing potassium levels may alter the
impact of potassium supplements as risk factor [36]: However,
numbers of patients with potassium supplements were too
small to conclude the effect of ace-inhibitors/sartans. With
respect to small sample size, less frequent co-medication such
as spironolactone or multiple combinations, e.g., ace-
inhibitors with/without concomitant thiazide diuretics, could
not be studied in stratified analyses. Propensity-matched co-
hort studies [19, 22] investigated the association between use
of potassium supplements and hospitalization for worsening
heart failure on long-term, reporting slightly increased hazard
ratios. Potassium supplements were discussed to be markers
of disease severity and use of higher doses of diuretics [22].
Furosemide and torsemide are commonly prescribed to en-
force diuresis in order to prevent heart failure decompensa-
tion. Usage indicates a potentially acute condition or deterio-
rating ejection fraction. We therefore adjusted our analysis for
the prescription of high-ceiling diuretics (sulfonamides).
Although odds ratios were attenuated, a positive significant
association remained. We can conclude that potassium sup-
plement is not solely dependent on high-ceiling diuretics as a
risk factor for hospitalization.
NSAIDs
Prescription of NSAIDs is contraindicated in patients suffering
from severe heart failure [37]. In addition, even in the general
population, recent NSAID use is associated with increased risk
for heart failure hospitalization [6, 7]. Huang et al. [8] conduct-
ed a case-crossover study in the National Health Insurance
Research Database in Taiwan, evaluating NSAID use in pa-
tients without a history of heart failure. They report a 1.58-fold
increased risk for a first heart failure hospitalization (adjusted
OR, 95% CI 1.40–1.79, hazard period 1–30 days, control pe-
riod 121–150 days). Although different patient collectives were
studied, our results (crude OR 1.8, 95% CI 1.39–2.33, and
adjusted OR 1.50 95% CI 1.14–1.97, time period 30 days)
are compatible with the overall increase in risk for heart failure
hospitalization reported in the literature. Previous studies also
found a dose-dependent effect. In addition, varying risks be-
tween individual NSAIDs were reported [7, 8, 10, 11].
In our study, only few patients were prescribed coxibs (n =
57), which did not allow for risk comparison with respect to
cyclooxygenase-2 selectivity. As previously mentioned, we
also evaluated paracetamol, metamizole sodium, and opioids
to assess potential confounding by pain as underlying condi-
tion. We also found an increased risk for hospitalization for
these drug classes. Positive associations remained after adjust-
ment (Supplement Table S6). Inhibition of prostaglandin syn-
thesis by NSAIDs is a well-known risk for reduced renal
function and increased peripheral resistance [7]. However,
the association for the other drugs, which do not share this
mechanism, is surprising and likely requires replication. This
finding suggests that renal function decrease may not be the
only factor contributing to the increased risk by NSAIDs.
Previous studies in current paracetamol users also reported
an increased risk for a first-diagnosed episode of heart failure
[10] and congestive heart failure [38]. Risk estimates were
higher among new users and in patients using high paraceta-
mol doses [10, 38]. Thus, pain itself may be a risk factor for
deteriorating heart failure or an early symptom of worsening
general condition. We could not consider over-the-counter
drugs in this study, which means that every prescription was
issued by a physician. It can be assumed that pain leading to
physician contact is of higher severity.
Amoxicillin/clavulanic acid
Prescriptions of amoxicillin and clavulanic acid can serve as
proxy for the underlying infection. Infections were reported to
be common precipitating factors for HF decompensation re-
quiring hospital admission, especially with respiratory infection
being common [12, 13, 15, 16]. Accordingly, our study found a
significantly increased risk for hospitalization after amoxicillin/
clavulanic acid prescription (OR 3.25, 15 days). Patients with
amoxicillin/clavulanic acid were more often co-prescribed for
mucolytics or drugs to treat asthma/COPD compared with the
whole study population. While an increased risk for severe
infections was previously reported for patients suffering from
COPD [12], our study found no significant difference in risk for
heart failure hospitalization comparing patients with and with-
out drug treatment of asthma/COPD.
In order to evaluate infection as risk factor, we extended the
analysis to other classes of antibiotics. Macrolides and
fluoroquinolones share a broad spectrum of indications with
amoxicillin/clavulanic acid and prescription numbers allowed
for their evaluation. We found a positive association for
macrolide antibiotics but not for fluoroquinolones. With lack-
ing diagnoses and wide ranges of indications for all three
antibiotic classes, reasons remain unclear. Nevertheless,
higher rates of respiratory infections in patients receiving
amoxicillin/clavulanic acid and macrolides are expected,
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suggesting some confounding by indication (and its severity):
co-prescription with mucolytics was stronger correlated for
amoxicillin/clavulanic acid and macrolides (Pearson correla-
tion coefficient 0.25 (95% CI 0.23–0.27, p < 0.0001) and 0.18
(95% CI 0.16–0.20, p < 0.0001)) than for fluoroquinolones
(0.07 (95% CI 0.05–0.09, p < 0.0001) within 30 days prior
to hospitalization. We also found comparably fewer chest x-
rays for fluoroquinolones (amoxicillin/clavulanic acid n = 62,
19.5%; macrolides n = 18, 16.8% and fluoroquinolones n = 26,
10.9%; 30 days). However, assessments of the urinary status
was more frequent for fluoroquinolones (fluoroquinolones n =
56, 23.4%; amoxicillin/clavulanic acid n = 36, 11.3%;
macrolides n = 11, 10.3%, 30 days), possibly reflecting urinary
tract infections as a milder type of bacterial infection in the
fluoroquinolone-treated patients.
Postma et al. [39] assessed heart failure events in patients
hospitalized for community-acquired pneumonia with respect
to antibiotic exposure. Compared with patients on beta-lactam
monotherapy, increased hazard ratios were reported for
clarithromycin and erythromycin. No increased risk was
found for ciprofloxacin, levofloxacin, and moxifloxacin (haz-
ard ratios 0.65 (non-significant), 0.27, and 0.50 (significant)),
respectively [39]. Our results suggest that respiratory infection
may be a stronger risk factor compared with other types of
bacterial infections. Amoxicillin/clavulanic acid is usually
well tolerated and may be preferred over other antibiotic clas-
ses in elderly and multimorbid patients. However, as clinical
differentiation between the diagnoses of heart failure and
pneumonia may be difficult, antibiotics may have been pre-
scribed for an exacerbation of heart failure in some cases.
Limitations
Our study has several limitations: First, Swiss claims data
is lacking diagnoses due to legal requirements. We used
DRG codes to identify patients with hospitalizations for
heart failure and shock. In Switzerland, DRGs reflect the
leading diagnosis during hospitalization rather than ad-
mission diagnoses. Therefore, development of heart fail-
ure during hospitalization cannot be ruled out. No infor-
mation on heart failure state like the New York Heart
Association “NYHA” classification was available.
Patients with and without known heart failure prior to
hospital admission were both evaluated. Thus, therapeutic
treatment and baseline risk for hospitalization might dif-
fer. Nevertheless, as each patient served as his/her own
controls, differences in patient characteristics were equal-
ly distributed over hazard and control groups. NSAIDs
and oral potassium supplements are available as over-
the-counter drugs in Switzerland. Thus, exposure may
not have been captured completely. However, as expenses
for these drugs are covered by the health insurance when
prescribed by physicians, and physician contact was
frequent, it is expected that over-the-counter purchases
may occur less frequently in our elderly patient popula-
tion. Amoxicillin/clavulanic acid and, to some extent, also
oral potassium supplements serve as proxies for underly-
ing diseases, namely bacterial infection and hypokalemia.
Details on type of infection and potassium levels unfortu-
nately were not available in the dataset. With respect to
the case-crossover design, exposure was calculated with
the assumption of immediate and actual intake of the pre-
scribed drugs. While NSAIDs are typically used on de-
mand for acute pain relief, some patients may have used
them continuously. On demand use may be disassociated
from dispensing times and thus carries the risk for expo-
sure misclassification [29]. While the case-crossover de-
sign controls for time-invariant confounding, which can
be seen as a particular strength, potential progression of
existing heart failure or general worsening of the overall
health condition in an elderly population introduce con-
founding [30]. We addressed this issue in several different
ways: we restricted the observation period to a maximum
of 6 months; we chose the control window for our main
analyses to be immediately before the hazard period and
adjusted our analyses for physician visits and prescrip-
tions of high-ceiling diuretics. Nevertheless, confounding
by disease progression may not have been eliminated
completely and result in potential overestimation of risk
estimates. Overlapping exposure from the control into the
subsequent hazard period, potentially shifting risk esti-
mates towards zero, was addressed by introducing a wash-
out period. Multiple control periods were used simulta-
neously to account for persistent users, which may have
resulted in upward-biased odds ratios [40]. Lastly, the
number of patients studied was small, resulting in insuf-
ficient statistical power especially when stratification for
co-mediation was performed. Thus, conclusions should be
drawn with caution and further studies are warranted.
Conclusion
Our study confirmed the previously reported increased
risk for prescription of NSAIDs and heart failure hospi-
talization. Additionally, prescription of oral potassium
supplements and amoxicillin/clavulanic acid was also
significantly associated with higher risk for hospitaliza-
tion. Underlying conditions such as pain, electrolyte im-
balances, and infections are likely contributing risk fac-
tors. The identification of precipitating factors for heart
failure hospitalizations becomes increasingly important
in an aging society. This knowledge should be used
by physicians to better identify patients at risk and to
intensify management early on.
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